Porida is the trade name and the generic name of the drug is Aliximab Injection, which has lipid-regulating properties and is used clinically for the prevention of cardiovascular events, primary hypercholesterolemia and mixed dyslipidemia, among other conditions. Aliximab Injection significantly reduces the risk of cardiovascular events in patients with acute coronary syndromes and is associated with a reduced risk of all-cause mortality. Adverse reactions to aliskirenumab injection include local injection site reactions (development of swelling, pain, and hardness), rash, pruritus, urticaria, allergic vasculitis, sore throat, and runny nose. It is important to note that this product is contraindicated in people who are allergic to the product, pregnant and lactating women; if a severe allergic reaction or adverse reaction occurs during use, treatment with Aliximab Injection must be discontinued and appropriate symptomatic therapy must be initiated.